

# Quanterix

## Dr. Mark Roskey Joins Quanterix Leadership Team

**Lexington, Mass. – September 16, 2014** - [Quanterix Corporation](#), a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that Dr. Mark Roskey has joined Quanterix' leadership team as Vice President and General Manager, Applications and Reagents. Roskey's responsibilities include the development and expansion of key application areas uniquely enabled by Simoa technology including assay development and the Accelerator, an internal lab dedicated to customer evaluations and service offerings on Simoa.

"The ability to measure proteins at the single molecule level opens up significant new opportunities to drive innovation in biology and directly impact discovery research and diagnostics," said Roskey, "I'm really excited to be joining Quanterix and look forward to helping customers see what biological advances are possible using ultrasensitive digital protein detection."

Roskey comes to Quanterix from PerkinElmer's Life Science and Technologies division where he was VP/GM of the America's Sales and Service organization. Prior to PerkinElmer, Roskey held senior level commercial and technical positions at Caliper Life Sciences, which was acquired by PerkinElmer in 2011. He has more than 25 years of experience in the life science industry focusing on product research and development, application development, strategic sales and marketing and overall business management for complex biological solutions and automated instrument systems. Dr. Roskey has a Ph.D. in Microbiology from the University of Notre Dame, and completed a postdoctoral fellowship in Molecular Immunobiology at the Harvard Medical School.

"We are very pleased to have a person of Mark's capability, experience and stature join the leadership team at a time when interest in Simoa for single molecule protein detection is growing rapidly," said Kevin Hrusovsky, Executive Chairman at Quanterix. "The ability to attract talent of his caliber speaks volumes for the technology and long-term potential for Quanterix to impact the world."

### About Quanterix

Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: [www.quanterix.com](http://www.quanterix.com)

###

### Contacts:

Nikki Festa/Caitlyn Keating

PAN Communications  
617-502-4300  
[quanterix@pancomm.com](mailto:quanterix@pancomm.com)

<sup>1</sup> Leporet. al., *British Journal of Urology*, October 2011

<sup>2</sup> Song et. al., *Journal of Immunological Methods*, September 2011

<sup>3</sup> Zetterberg et. al., *PLoS ONE*, December 2011